{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:53:37Z","timestamp":1789890817763,"version":"4.0.1"},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,3,3]],"date-time":"2003-03-03T00:00:00Z","timestamp":1046649600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study was designed to define the effect of low\u2010dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified 5\u2010drug cocktail procedure consisting of caffeine, mephenytoin, metoprolol, chlorzoxazone, and midazolam was performed to simultaneously assess in vivo activity of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and CYP3A, respectively. The activities were assessed on 4 occasions including at baseline, after 7 and 14 daily doses of aspirin, and at 7 days after discontinuation of aspirin. Concentrations of parent drugs and corresponding metabolites in biologic samples were assayed by reversed\u2010phase HPLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both 7\u2010day and 14\u2010day aspirin intake increased the activity of CYP2C19 significantly, as indicated by 4\u2010hydroxymephenytoin urinary recovery (<jats:italic>P<\/jats:italic> &lt; .001). Induction of low\u2010dose aspirin on CYP2C19 was time\u2010dependent. CYP3A activity indices increased moderately but significantly by both 7\u2010day and 14\u2010day aspirin treatment (<jats:italic>P<\/jats:italic> &lt; .05), but the percentage changes in CYP3A activity indices were not significant. Low\u2010dose aspirin had no effect on CYP1A2, CYP2D6, and CYP2E1 in vivo activity by either 7\u2010day or 14\u2010day treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The effect of low\u2010dose aspirin on CYPs was enzyme\u2010specific. Both 7\u2010day and 14\u2010day low\u2010dose aspirin induced the in vivo activities of CYP2C19 but did not affect the activities of CYP1A2, CYP2D6, and CYP2E1. The effect of low\u2010dose aspirin on CYP3A activity awaits further confirmation. When low\u2010dose aspirin is used in combination with drugs that are substrates of CYP2C19, doses of the latter should be adjusted to ensure their efficacy.<\/jats:p><jats:p><jats:italic>Clinical Pharmacology &amp; Therapeutics<\/jats:italic> (2003) <jats:bold>73<\/jats:bold>, 264\u2013271; doi: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1067\/mcp.2003.14\">10.1067\/mcp.2003.14<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1067\/mcp.2003.14","type":"journal-article","created":{"date-parts":[[2003,3,26]],"date-time":"2003-03-26T02:25:50Z","timestamp":1048645550000},"page":"264-271","source":"Crossref","is-referenced-by-count":51,"title":["Isozyme\u2010specific induction of low\u2010dose aspirin on cytochrome P450 in healthy subjects"],"prefix":"10.1111","volume":"73","author":[{"given":"Xiao\u2010Ping","family":"Chen","sequence":"first","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Rong","family":"Tan","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song\u2010Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong\u2010Sheng","family":"Ou\u2010Yang","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Hao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Research Institute Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,3,3]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1067\/mcp.2003.14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T19:17:19Z","timestamp":1700162239000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1067\/mcp.2003.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1067\/mcp.2003.14"],"URL":"https:\/\/doi.org\/10.1067\/mcp.2003.14","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}